Contact Dermatitis Pipeline Review 2021

Contact dermatitis (CD) is a disorder of skin categorized by itching, redness, and vesiculation.  In chronic cases, scaly lichenification and desquamation may also occur.  CD is caused due to being in contact with environmental substances that stimulates an allergic and/or irritant response.  The first step in making the diagnosis is high clinical suspicion of an allergic contact dermatitis (ACD).  Person suffering from acute or chronic dermatitis is indicated by patch testing if an underlying or secondary ACD is suspected.

Contact dermatitis (CD) is a common skin disorder with a projected 5.7 million physician visits annually.  All age group people are affected, with a slight higher preference is seen in female. According to data published by World Allery Organization, CD estimates for around 85 – 95% of all occupational skin disease in developed countries. The most common clinical manifestation is hand dermatitis, affecting 2 – 6% of this population.

In March 2020, Pfizer announced a positive top-line results for Abrocitinib which is in Third Phase 3 Trial of for Moderate to Severe Atopic Dermatitis. It showed improvements in skin clearance, disease severity and extent, and itch

Approximately 60% of pipeline drugs for contact dermatitis are in phase 2 clinical stage. Several government institutes and research organizations are conducting clinical trials combined with pharmaceutical companies to treat and prevent contact dermatitis.

Report Description

The report on Contact dermatitis- Pipeline Review, 2020 provides comprehensive information regarding drugs in the pipeline by indication or molecule for contact dermatitis. The report provides a complete analysis of the stage of development, mechanism of action (MoA), drug target route of administration (RoA) and molecule type. The report helps in tracking and identifying emerging players in the market and their portfolios enhance decision-making capabilities and assists companies in developing growth strategies by providing a complete overview of R&D activities.

Report Scope

• Assessment of pipeline products based on various stages of devolvement.
• Provides an overview of the global therapeutic landscape of Contact dermatitis (Infectious Disease).
• Provides comprehensive details of pipeline products based upon companies and universities/research institutes overviews
• The report provides descriptive features regarding drug profiles for the pipeline products which comprise, product description, R&D brief, descriptive licensing and collaboration details, MoA & other developmental activities.
• Latest news, articles, press-release, and related conferences
• Provides detailed analysis regarding significant competitor and insights to formulate effective R&D development strategies

• Create effective counter-strategies to gain competitive advantage and identify emerging players with a potentially strong product portfolio
• Build strategic initiatives by understanding the focus areas of leading companies
• Identify strategies to diversify R&D focus to drive the growth in business and plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Analysis of the reason behind the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline